PHARMExcel provides specialist Hepatology & Liver Disease CRO Services for sponsors conducting clinical trials across a wide range of liver conditions. We work with biotechs, medtech companies, charities and NHS or academic sponsors to help deliver hepatology studies that are scientifically robust, operationally realistic and aligned with the needs of patients, investigators and specialist sites.
Our services are focused on the clinical trial stage, helping sponsors navigate the practical and regulatory challenges of liver disease research through tailored governance, oversight and hands-on clinical operations. This includes studies in MASH/NASH, cirrhosis, acute and chronic liver failure, viral hepatitis, hepatocellular carcinoma and rare liver diseases such as primary biliary cholangitis, where careful protocol planning, endpoint selection and site feasibility are essential.
Hepatology and liver disease clinical trials explained
Hepatology clinical trials are designed to evaluate treatments and interventions for liver diseases that can vary widely in severity, progression and patient burden. These studies often involve complex endpoints, high screen failure rates and patient populations with multiple comorbidities, including metabolic disease, alcohol-related illness and systemic complications associated with advanced liver dysfunction.
Because many liver disease patients are clinically vulnerable and may require specialist monitoring, study design must balance scientific rigour with practical feasibility. Visit schedules, safety oversight and endpoint collection all need to fit the realities of specialist hepatology care if sponsors are to generate high-quality data in a way that works for both patients and investigators.
Designing complex hepatology and liver disease trials
Liver disease studies can be difficult to deliver because patient populations are often diverse and referral pathways may be highly specialist. Conditions such as cirrhosis, acute or chronic liver failure, viral hepatitis and MASH/NASH can present with very different clinical profiles, while rare liver diseases such as primary biliary cholangitis may require access to experienced centres and carefully managed referral routes.
PHARMExcel helps sponsors shape and deliver hepatology protocols that reflect these realities. Our role is to ensure that studies are designed around practical site capability, realistic patient pathways and the operational demands of complex liver disease research. This includes helping sponsors plan around challenging inclusion criteria, vulnerable patient populations and the need for careful coordination across specialist hepatology services.
Specialist centres, imaging pathways and study oversight
Many hepatology trials depend on access to centres with the right clinical expertise and diagnostic pathways, particularly where imaging, biopsy or specialist disease staging are central to the protocol. PHARMExcel does not perform these procedures directly. Instead, we provide governance and oversight by helping sponsors identify the most appropriate hepatology centres, referral routes and specialist partners for the study.
This is particularly important in advanced liver disease and rare hepatology research, where access to the right centres can influence both study feasibility and data quality. By aligning sponsors with sites that have the appropriate experience, infrastructure and patient pathways, we help ensure that protocol requirements are delivered consistently and in line with study expectations. Our involvement in the Liver Dialysis Device DIALIVE Proves Safe And Effective study is an example of this in practice, supporting a complex device trial in an advanced liver disease setting through specialist centre engagement and robust clinical oversight.
Regulatory support and hepatology trial governance
PHARMExcel supports hepatology studies with the regulatory and governance input needed to keep trials compliant, well documented and operationally sound. This includes support with ethics committee and regulatory submissions, safety reporting, monitoring oversight, medical writing and data management processes that reflect the needs of the protocol and the patient population.
Hepatology research often involves clinically vulnerable participants, intensive monitoring and endpoints that require careful documentation across multiple visits and specialist services. Our role is to help sponsors maintain data quality, protocol fidelity and audit readiness through clear oversight and proportionate clinical trial management.
"The PHARMExcel team consistently exceeds expectations, offering a depth of expertise and attention to detail that sets them apart. Their ability to adapt to the needs of our projects while maintaining the highest standards makes them an invaluable CRO partner in clinical research."
Prof. Rajiv Jalan, Professor of Hepatology, University College London
Patient-centred liver disease trial delivery
Patient experience is especially important in hepatology research because many liver conditions are associated with fatigue, pain, frailty, infection risk and significant treatment burden. In advanced disease, the demands of travel, repeated assessments and specialist appointments can affect both participation and retention, making it essential that studies are designed and delivered with practicality and sensitivity.
PHARMExcel works with sponsors and sites to ensure that trial processes are realistic for participants, with careful attention to visit burden, communication and operational feasibility. We do not directly recruit patients, but we provide governance and oversight of site-led recruitment pathways and support realistic enrolment planning through the right network of hepatology centres and investigators.
Partner with PHARMExcel for hepatology and liver disease CRO services
Sponsors choose PHARMExcel because we combine therapeutic understanding, agile clinical operations and a quality-driven approach to trial delivery. As a smaller CRO, we offer direct access to senior staff, continuity of team and the flexibility to shape our involvement around the needs of the study, whether that means full service hepatology CRO support or focused assistance with specific parts of the trial.
Our aim is to reduce operational burden, support regulatory readiness and help sponsors deliver high-quality hepatology clinical trials that are feasible in practice as well as robust on paper. For organisations looking for a collaborative and responsive CRO partner in liver disease research, PHARMExcel provides practical expertise grounded in real-world clinical trial delivery.
Hepatology and liver disease study FAQs
Which liver conditions can PHARMExcel support?
PHARMExcel can support clinical trials across a broad range of hepatology indications, including MASH/NASH, cirrhosis, acute and chronic liver failure, viral hepatitis, hepatocellular carcinoma and rare liver diseases such as primary biliary cholangitis. We can also support studies where specialist hepatology input, complex referral pathways and vulnerable patient populations are central to successful delivery.
Does PHARMExcel cover both pre-clinical and clinical liver studies?
No. PHARMExcel does not provide pre-clinical or laboratory research services. Our focus is on the clinical trial stage, where we support sponsors through governance, regulatory strategy, site coordination and operational delivery.
How are imaging and biopsy endpoints handled in hepatology trials?
PHARMExcel does not perform imaging or biopsy procedures directly. Instead, through our comprehensive network, we provide access to sites and specialist centres that have the right diagnostic capability, specialist expertise and site processes in place to deliver these assessments consistently and in line with protocol requirements.
How does PHARMExcel approach recruitment in hepatology studies?
PHARMExcel does not directly recruit patients. Instead, we provide governance and oversight of site-led recruitment by helping sponsors identify suitable hepatology centres, assess realistic referral pathways and work with investigators who understand the local patient population and study requirements.
How does PHARMExcel ensure regulatory compliance in hepatology trials?
We support sponsors with ethics committee and regulatory submissions, safety reporting, monitoring oversight, data management and trial documentation in line with Good Clinical Practice and relevant regulatory expectations. Our quality-driven approach helps ensure studies remain compliant, well governed and audit ready.
Why choose PHARMExcel as a hepatology CRO?
Sponsors choose PHARMExcel for our responsive, quality-led approach to clinical trial delivery. As a smaller CRO, we provide direct access to senior staff, continuity of team and practical oversight across the trial lifecycle, helping hepatology studies remain feasible, compliant and patient centred.